Date:
Tuesday, March 20, 2018, 12:00pm to 1:00pm
Location:
Dana-Farber Cancer Institute, Smith Building, Room 308/309, Jimmy Fund Way, Boston, MA
RSVP: Amy Lee (alee@biolegend.com)
Presenter:
Christopher Gould, PhD
Technical Applications Scientist, BioLegend
In recent years, the involvement of immune cells in controlling cancers has come to the forefront of therapy and research. It is now evident that immune cells are central to the three “E’s” of cancer immunoediting: Elimination, Equilibrium, and Escape, as tumors devise a diverse set of mechanisms to overcome immune control. One critical mechanism is the expression of immune checkpoint ligands on tumors that engage checkpoint receptors on immune cells, resulting in immune inactivation and tumor escape. Targeting this pathway with blocking antibodies has shown real promise, but continued research is essential.